Reference(s)
Click here to return to the Reference Table

Category: Carcinomas
Cancer type: Liver
Descriptor: Reviews


Reference Number: 746
Osada S, Yoshida K. Application of biological study for met expression to cancer therapy. Anticancer Agents Med Chem. 10, 58-63 (2010)
PubMed link      E-mail link

Reference Number: 1007
Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 15, 2207-14 (2009)
PubMed link      E-mail link

Reference Number: 1193
Zhu AX. Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives. Semin Oncol. 39, 493-502 (2012)
PubMed link      E-mail link

Reference Number: 1357
Goyal L1, Muzumdar MD, Zhu AX. Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res. 19, 2310-8 (2013)
PubMed link      E-mail link

Reference Number: 1369
Marquardt JU, Thorgeirsson SS. Linking MLL and the HGF-MET signaling pathway in liver cancer. J Clin Invest. 123, 2780-3 (2013)
PubMed link      E-mail link

Reference Number: 1690
Rota Caremoli E, Labianca R. Tivantinib: critical review with a focus on hepatocellular carcinoma. Expert Opin Investig Drugs. 23, 1563-74 (2014)
PubMed link      E-mail link

Reference Number: 1789
Johnson PJ. How do mechanisms of hepatocarcinogenesis (HBV, HCV, and NASH) affect our understanding and approach to HCC? Am Soc Clin Oncol Educ Book. (2013)
PubMed link      E-mail link

Reference Number: 1855
Choi KJ, Baik IH, Ye SK, Lee YH. Molecular Targeted Therapy for Hepatocellular Carcinoma: Present Status and Future Directions. Biol Pharm Bull. 38, 986-91 (2015)
PubMed link      E-mail link

Reference Number: 1856
Qi XS, Guo XZ, Han GH, Li HY, Chen J. MET inhibitors for treatment of advanced hepatocellular carcinoma: A review. World J Gastroenterol. 21, 5445-53 (2015)
PubMed link      E-mail link